Dynavax Technologies Corporation Stock News

Dynavax's core asset, HEPISLAV-B, saw a 69% increase in sales in FY23, making the company cash flow positive. The company's CpG 1018 vaccine candidates are advancing in mid-stage trials, with Heplisav

Dynavax Technologies Corporation (DVAX) Q4 2023 Earnings Call Transcript

Dynavax Technologies (DVAX) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.01. This compares to earnings of $0.45 per share a year ago.

Dynavax Technologies (DVAX) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed t

EMERYVILLE, Calif. , Jan. 3, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, tod

Today, we take another look at Dynavax Technologies Corporation, which experienced a boost in revenue from the Covid pandemic, but this has now nearly completely diminished. However, the company's cor

Here we present three biotech stocks, CRSP, ITCI and DVAX, which most analysts on Wall Street are optimistic about. These companies have upside potential for 2024, backed by strong fundamentals.

New drug approvals and pipeline progress are likely to help maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position GILD, CRSP, ACAD,

EMERYVILLE, Calif. , Nov. 20, 2023 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, t

Here is how Dynavax Technologies (DVAX) and Cardinal Health (CAH) have performed compared to their sector so far this year.

Start Time: 16:30 January 1, 0000 4:59 PM ET Dynavax Technologies Corporation (NASDAQ:DVAX ) Q3 2023 Earnings Conference Call November 02, 2023, 16:30 PM ET Company Participants Ryan Spencer - CEO Don

On Dynavax's (DVAX) third-quarter earnings call, investors' focus is likely to be on the sales performance of the company's hepatitis B vaccine, HEPLISAV-B.

EMERYVILLE, Calif., Oct. 19, 2023 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, tod

Here, we discuss some reasons why investing in Dynavax Technologies (DVAX) stock now may turn out to be a prudent move.

Dynavax Technologies (DVAX) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed t